Bristol Myers Squibb Co.

BMY · NYSE · Healthcare · Drug Manufacturers General

下次财报：2026年10月29日 · 开盘前

US$62.88-1.6%9月29日收盘

1M: -6.0%
6M: +4.1%
1Y: +39.0%
5Y: +29.0%

Bristol Myers Squibb discovers, makes and sells prescription medicines for cancer, blood disorders, immune conditions, heart disease and mental health conditions.

基于 Bristol Myers Squibb Co. 自己向 SEC 提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

完整财务报表 →

关于Bristol Myers Squibb Co.

Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.

总部: Lawrence Township, New Jersey (Princeton area)
成立于: 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
员工人数: Approximately 32,500 (December 31, 2025, high)
上市于: NYSE
财年结束: December 31

怎么赚钱

Prescription medicines, plus royalties and alliance-related revenue100%

各项收入占比是对FY2025的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.

再显示 3 项

Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.

谁在买5

Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
Retail pharmacies, hospitals and clinics that purchase or dispense medicines.

再显示 2 项

Government agencies and public health programs that buy medicines or cover their cost.
Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.

靠什么支撑，什么会击垮它

业务依赖什么

1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).

与同行业相比处在什么位置

三项评分，每一项都是相对我们在Drug Manufacturers General覆盖的 21 家公司的百分位。刻意分开而不揉成一个总分：便宜、上涨和经营得好是三件不同的事，一个数字会把它们是哪一件藏起来。

动量

74在同行业中满分 100

高于行业内多数公司

截至一个月前的 12 个月48.0%

截至一个月前的 6 个月9.1%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

68在同行业中满分 100

高于行业内多数公司

每单位价格对应的利润7.23%

每单位价格对应的现金8.91%

每单位价格对应的营收38.30%

每单位价格对应的资产14.38%

整个企业对应的经营利润—

这些是收益率，所以数值越高越便宜——亏损的公司会排在最后，而不是被剔除。便宜不等于好：高收益率往往意味着股价是有原因才跌下来的。由 5 项指标中的 4 项混合而成。

资本配置

3/3克制

3 项检验未披露

资本回报率—

股东回报率3.93%

股本数量，3 年-4.8%

净债务 / EBITDA—

内部人，12 个月—

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报披露不足，无法计算
债务与盈利之比没有可比的盈利用来衡量债务
回馈给股东的现金每年 3.9% 用于回购和分红
三年间的股本数量三年间股本数量减少 4.8%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入没有内部人在公开市场交易的记录

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.

5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.

可能出什么问题

1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.